KD-414
KD-414
Main page
2553576

KD-414

logo
Community Hub0 subscribers
What are your thoughts?
Be the first to start a discussion here.
Be the first to start a discussion here.
KD-414

KD-414 is a COVID-19 vaccine candidate developed by Japanese biotechnology company KM Biologics Co. Results of a phase 1/2 clinical trial for this vaccine were released as a preprint in June 2022.

See all
User Avatar
No comments yet.